Status:
COMPLETED
SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients
Lead Sponsor:
National Cancer Institute, Thailand
Collaborating Sponsors:
Mahidol University
Conditions:
COVID-19
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy. Fu...
Detailed Description
A total of 311 participants, including 107 patients with solid tumor and 204 healthy volunteers who received 2 doses of CoronaVac were recruited from National Cancer Institute of Thailand between 2020...
Eligibility Criteria
Inclusion
- Male or Female age at least 18 years
- Patients with a diagnosis of solid tumors
- Ability to understand the patient information and study consent. Signed and dated written informed consent must be available before performing any study-related procedure
- Willing and able to comply with the study procedures.
- Willing to receive a Coronavac vaccine (Sinovac).
Exclusion
- Patients who cannot provide consent
Key Trial Info
Start Date :
March 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 25 2022
Estimated Enrollment :
311 Patients enrolled
Trial Details
Trial ID
NCT05313074
Start Date
March 23 2021
End Date
February 25 2022
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute
Ratchathewi, Bangkok, Thailand, 10400